Compare FSV & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSV | LEGN |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | FSV | LEGN |
|---|---|---|
| Price | $155.76 | $21.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $214.25 | $69.58 |
| AVG Volume (30 Days) | 222.6K | ★ 2.6M |
| Earning Date | 02-04-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ 26.06 | N/A |
| EPS | ★ 3.03 | N/A |
| Revenue | ★ $5,479,473,000.00 | $909,045,000.00 |
| Revenue This Year | $6.04 | $68.83 |
| Revenue Next Year | $6.89 | $51.27 |
| P/E Ratio | $51.19 | ★ N/A |
| Revenue Growth | 11.13 | ★ 74.75 |
| 52 Week Low | $147.23 | $21.19 |
| 52 Week High | $209.66 | $45.30 |
| Indicator | FSV | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 25.47 |
| Support Level | $147.23 | $21.19 |
| Resistance Level | $155.86 | $28.97 |
| Average True Range (ATR) | 3.15 | 1.27 |
| MACD | 1.00 | -0.26 |
| Stochastic Oscillator | 69.33 | 9.13 |
FirstService Corp operates in two business divisions: FirstService Residential and FirstService Brands. FirstService Residential has service contracts to manage thousands of residential communities, including high-, medium-, and low-rise condominiums and co-operatives. FirstService Brands generates the majority of the company's revenue and provides property services to residential and commercial customers through the following brands: California Closets; Paul Davis Restoration; CertPro Painters; Pillar to Post; Floor Coverings International; College Pro Painters; and Service America. The company earns the majority of its revenue in the United States, with the remaining revenue generated in Canada.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.